WELCOME TO
BSG LIVE’25

This promotional symposium is organised and funded by Celltrion Healthcare UK Ltd. for UK based Healthcare professionals and other relevant decision makers (ORDMs).

This symposium is intended for HCPs or ORDMS who are budget and formulary decision makers

Chair: 
Professor Shaji Sebastian, Consultant Gastroenterologist and IBD Service Lead at Hull Royal Infirmary, Hull University Teaching Hospitals NHS Trust.

Speaker:
Dr. Fraser Cummings, Consultant Gastroenterologist, University Hospital Southampton NHS Foundation Trust.

Agenda:

Setting the scene – the current biosimilar landscape in IBD and treatment targets in IBD

Introducing the Celltrion IBD portfolio including SteQeyma®▼(ustekinumab) and Remsima® (infliximab) SC data.

Presentation of a Southampton Biosimilar Business case study.

Considerations when assessing value in biologicals and the Celltrion value proposition.

Panel discussion and Q&A

AE reporting information and Prescribing information can be found below

Adverse events should be reported.

Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App store.

Adverse events should also be reported to Celltrion Healthcare by emailing [email protected]
or calling
+44 (0) 1753 983 500

For full indications, contraindications and information on special warnings, precautions and adverse events, please refer to the Summary of Product Characteristics.

Please click here to view the Remsima® (infliximab) IV prescribing information:

Please click here to view the Remsima® (infliximab) SC prescribing information:

Please click here to view the Yuflyma®▼(adalimumab) prescribing information:

Please click here to view the SteQeyma® (ustekinumab) prescribing information:

UK–25-00086 June 2025